Form 4: Cognition Therapeutics Director Receives Significant Equity Grant

A recent SEC Form 4 filing reveals that Brett P. Monia, a Director at Cognition Therapeutics Inc. (CGTX), was granted 34,000 Restricted Stock Units (RSUs) as part of his compensation.

Summary

• Brett P. Monia, a Director of Cognition Therapeutics Inc. (CGTX), acquired 34,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 18, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• The RSUs were granted at a price of $0.00 per unit, which is typical for equity compensation.
• Following this transaction, Mr. Monia beneficially owns 48,500 shares of Common Stock.
• The RSUs are set to vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, contingent upon Mr. Monia's continuous service as a director.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While it's a compensation event rather than a direct cash investment, the grant of equity to a director aligns their interests with shareholders and is a common practice for incentivizing long-term commitment. It indicates stability in the board's composition and compensation strategy.

Positives

• The grant of Restricted Stock Units to a director aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a common method for retaining and incentivizing key personnel.

Risks

• The vesting of the RSUs is subject to the reporting person's continuous service as a director, meaning the shares could be forfeited if service is terminated before the vesting date.

Future Outlook

The 34,000 Restricted Stock Units granted to Director Brett P. Monia are scheduled to vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, subject to his continuous service.

Industry Context

This filing represents a standard equity compensation event for a director, common across publicly traded companies to align management and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) at a $0.00 price is a standard practice for equity-based compensation in the biotechnology and pharmaceutical industries, similar to grants observed at companies like Biogen Inc. or Eli Lilly and Company for their non-employee directors.
• The vesting schedule, tied to a specific future date or the next annual meeting, is also a common structure for director equity awards, aiming to incentivize continued service and long-term commitment.

Related Party Transactions

• The acquisition of 34,000 Restricted Stock Units by Director Brett P. Monia from Cognition Therapeutics Inc. constitutes a related party transaction, representing equity compensation for his service.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the company's stock performance, potentially leading to decisions that enhance shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The 34,000 Restricted Stock Units will vest on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, provided continuous service as a director.

Key Dates

Keywords

Cognition Therapeutics, CGTX, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Beneficial Ownership